Biora Therapeutics, Inc.

Progenity, Inc.

Other

Bt Bidco, Inc.

Jones, Ryan Elliott

Drlik, Mark Sasha

Nguyen, Tuyen

Niknia, Iman

Muller, Nathan John

Abercombie, Stuart Robert

Salt, Nicholas Mark

Stevens, Nia Eleri

Jones, Mitchell Lawrence

Mudge, Edward

Bunce, Christopher Ian

Christopher Loren Wahl

Mitchell Lawrence Jones

Sharat Singh

Harry Stylli

Mark Sasha Drlik

Nathan John Muller

Iman Niknia

Jeffrey A Shimizu

Nelson Quintana

Tuyen Nguyen

Nia Eleri Stevens

Stuart Robert Abercrombie

Kevin Howe

Christopher Ian Bunce

Edward Mudge

Nicholas Mark Salt

Kate LeeAnn Bechtel

Aaron Olafur Laurence Philippsen

Ryan Elliott Jones

Pejman Rahimian

Yi Liu

Arana Perera

Paul D Smith

Robert Stanford Magyar

Nicholas David Allan

Brian Pak

Allison Luo

John Mitchell McLean

Ryan Paul McGuinness

Alec John Lillis

Gene Alan Wey

Andrew Carlos Garland

Aruna Perera

Shaoying Lee

Kevin David Howe

Kate Lee Ann Bechtel

Mitchel Lawrence Jones

This disclosure features methods and compositions for treating inflammatory disorders or conditions that arise in a tissue originating from the endoderm using an immune modulator.

Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine

This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a JAK or other kinase inhibitor.

Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor

This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with an immunosuppressant.

Treatment of a disease of the gastrointestinal tract with an immunosuppressant

The present disclosure relates to gastrointestinal (GI) tract detection methods, devices and systems.

Gastrointestinal tract detection methods, devices and systems

Ingestible devices can directly deliver therapeutic agents to desired tissue(s) of the GI tract of a subject, such as the submucosa, the mucosa, and/or the mucus layer of the GI tract, and methods of using the same. The ingestible devices can deliver therapeutic agents in a safe, effective, and reliable manner. The disclosure also provides pharmaceutical compositions for use in methods of treating a disease or condition in a subject in need thereof.

Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Ingestible devices are disclosed that provide very high localization accuracy for the devices when present in the GI tract of a body. Related systems and methods are also disclosed.

Localization systems and methods for an ingestible device

This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a JAK inhibitor.

Treatment of a disease of the gastrointestinal tract with a JAK inhibitor and devices

Ingestible devices capable of delivering a dispensable substance, such as, for example, a therapeutic agent, as well as related components, systems and methods, are disclosed. A removably attachable storage reservoir configured to be used with an ingestible device and capable of storing dispensable substance, such as, for example, a therapeutic agent, as well as related components, systems and methods, are also disclosed.

Ingestible device for delivery of a dispensable substance

This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with IL-10 or an IL-10 agonist.

Treatment of a disease of the gastrointestinal tract with IL-10 or an IL-10 agonist

This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with an IL-12/IL-23 inhibitor.

Treatment of a disease of the gastrointestinal tract with an IL-12/IL-23 inhibitor released using an ingestible device

The present disclosure relates to methods of collecting and testing bacteria containing samples from within the gastrointestinal (GI) tract of a subject. The methods may include disposing an ingestible device in the GI tract, collecting a bacteria-containing sample from the GI tract, selectively lysing eukaryotic cells in the sample by combining the sample with a dried reagent, exposing bacteria in the sample to resazurin in the ingestible device to produce resorufin, emitting light from the ingestible device, the emitted light being filtered through an optical filter to control for scatter so that the light interacts with the resorufin to produce fluorescence, and measuring a total fluorescence from the resorufin; or a rate of change of fluorescence from the resorufin as a function of time within the GI tract of the subject; and correlating the measured parameter to a number of viable bacterial cells in the sample.

Methods for collecting and testing bacteria containing samples from within the gastrointestinal tract

Various embodiments are described herein for a recovery tool kit system including a recovery tool and an associated retrieval method for retrieving and storing an ingestible device.

Ingestible device recovery system

A method of treating a disease or condition in a subject in need thereof is disclosed. The method comprising: trans-epithelially administering a dispensable substance to the gastrointestinal (GI) tract of the subject by orally administering an ingestible device comprising the dispensable substance to the subject. The ingestible device is configured for trans-epithelial delivery of the dispensable substance to the GI tract of the subject and the dispensable substance comprises a pharmaceutical formulation comprising a therapeutically effective amount of a glucagon receptor agonist or a glucagon-like peptide-1 (GLP-1) receptor agonist. The ingestible device releases the dispensable substance as at least one jet to a desired location of the GI tract of the subject.

Growing community of inventors

San Diego, CA, United States of America

Christopher Loren Wahl